By Sherri Oslick —

About
Court Report:  Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.

Paratek Pharmaceuticals, Inc. v. Kappos
1:09-cv-02425; filed December 28, 2009 in the
District Court of the District of Columbia

Review and correction of the patent term adjustment
calculation made by the U.S. Patent and Trademark Office for U.S. Patent No.
7,553,828 ("9-Aminomethyl Substituted Minocycline Compounds," issued
June 20, 2009).  View the complaint here.

Administrators of the Tulane Educational Fund et al. v. Ipsen
Pharma, S.A.S. et al.
1:09-cv-02428; filed December 28, 2009 in the
District Court of the District of Columbia

• Plaintiffs:  Administrators of the Tulane
Educational Fund; David H. Coy
• Defendants:  Ipsen Pharma, S.A.S.; Ipsen,
S.A.

Correction of inventorship of U.S. Patent Nos.
6,903,186 ("Analogues of GLP-1," issued June 7, 2005), 7,268,213 (same
title, issued September 11, 2007) and 7,235,628 (same
title, issued June 26, 2007), and all related applications, directed to peptide
analogs of the human glucagon-like peptide hormone (GLP-1), to add an inventor
from Tulane University.  View the
complaint here.

Medicines Company v. Pliva Hrvatska d.o.o. et al.
1:09-cv-01000; filed December 28, 2009 in the
District Court of Delaware

• Plaintiff:  Medicines Company
• Defendants:  Pliva Hrvatska d.o.o.; Pliva d.d.;
Barr Laboratories Inc.; Barr Pharmaceuticals Inc.; Barr Pharmaceuticals LLC;
Teva Pharmaceuticals USA Inc.; Teva Pharmaceutical Industries Ltd.

Medicines Company v. Teva Parenteral Medicines Inc. et al.
1:09-cv-00999; filed December 28, 2009 in the
District Court of Delaware

• Plaintiff:  Medicines Company
• Defendants:  Teva Parenteral Medicines Inc.; Teva
Pharmaceuticals USA Inc.; Teva Pharmaceutical Industries Ltd.

The complaints in these cases are substantially
identical.  Infringement of U.S.
Patent No. 7,598,343 ("Pharmaceutical Formulations of Bivalirudin and
Process of Making the Same," issued October 6, 2009) following a Paragraph
IV certification as part of defendants' filing of an ANDA to manufacture a
generic version of The Medicines Company's Angiomax® (bivalirudin, used as an
anticoagulant in patients with unstable angina undergoing percutaneous
translurninal coronary angioplasty).  View the Pliva complaint here.

Medicis Pharmaceutical Corp. v. Barr Laboratories et al.
1:09-cv-03464; filed December 28, 2009 in the
District Court of Maryland

• Plaintiff:  Medicis Pharmaceutical Corp.
• Defendants:  Barr Laboratories, Inc.; Teva
Pharmaceuticals USA, Inc.

Infringement of U.S. Patent No. 5,908,838 ("Method
for the Treatment of Acne," issued June 1, 1999) following a Paragraph IV
certification as part of defendants' supplemental filing to their ANDA to
manufacture a generic version of Medics' Solodyn® (minocycline hydrochloride
extended release tablets, used to treat acne).  View the complaint here.

Abbott Laboratories Inc. et al. v. Apotex Inc. et al.
1:09-cv-00990; filed December 23, 2008 in the
District Court of Delaware

• Plaintiffs:  Abbott Laboratories Inc.; Abbott
GmbH & Co KG
• Defendants:  Apotex Inc.; Apotex Corp.

Infringement of U.S. Patent No. 5,436,272 ("Treatment
of Obesity, issued July 25, 1995) following a Paragraph IV Certification as
part of Apotex's filing of an ANDA to manufacture a generic version of Abbott's
Meridia® (sibutramine hydrochloride, used to treat obesity).  View the compliant here.